#Bioretec #Finland #Helsinki #RemeOs #Activa

Bioretec Ltd Launches a New Rights Issue

Bioretec Ltd, a pioneering company in the medical devices sector from Finland, has recently announced a significant rights issue aimed at enabling its existing shareholders to subscribe to up to 1,477,828,416 new shares. This offering was made public on 27 March 2026 and represents a major step in furthering the company's innovative developments in orthopedic care.

The newly offered shares have been priced at EUR 0.01 each, highlighting Bioretec's commitment to providing its shareholders with an attractive opportunity to participate in the growth of the company. In conjunction with this rights issue, Bioretec has prepared an exemption document, adhering to the European Union’s Prospectus Regulation requirements. This document aims to provide clear and comprehensive information to shareholders about the offering.

Available as of 2 April 2026, this exemption document can be accessed on the Bioretec website, both in Finnish and with an unofficial English translation, allowing shareholders from various regions to understand the terms of the rights issue.

Subscription Period and Trading Rights

The subscription for these new shares will officially commence on 7 April 2026 at 9:30 AM Finnish time and is set to conclude on 21 April 2026 at 4:00 PM. During this period, shareholders will have the opportunity to trade their subscription rights on the Nasdaq First North Growth Market in Finland between 7 April and 15 April 2026. This flexibility is intended to enhance market participation and liquidity for investors in the offering.

Bioretec is also working with DNB Carnegie Investment Bank AB as the sole global coordinator for this rights issue, ensuring that investors have access to expert guidance and support throughout the process. In addition to their financial advisors, Krogerus Attorneys Ltd, along with Borenius Attorneys Ltd, will provide legal counsel to ensure compliance and protect shareholder interests.

Company Overview and Innovation

Founded in Finland, Bioretec has positioned itself as a leader in transforming orthopedic treatment with its fully biodegradable implant technologies. The company is renowned for its strong focus on enhancing bone growth and accelerating fracture healing, a crucial aspect of orthopedic surgery. Notably, their RemeOs™ product line utilizes advanced magnesium alloys and hybrid composites, setting a new standard for surgical implants that are absorbed naturally by the body, negating the need for subsequent removal operations.

This innovative approach not only aims to improve surgical outcomes but also enhances the overall patient experience, making recovery less invasive and more efficient. For example, Bioretec received market authorization for its RemeOs products in the U.S. in March 2023, followed by CE marking in Europe in January 2025, showcasing its rapid advancement in the medical device field.

Bioretec’s Activa product line enhances their offerings with entirely bioabsorbable orthopedic implants, targeting a wider range of applications for both adult and pediatric patients. This underscores their dedication to pioneering solutions that resonate with the changing needs in orthopedic care.

Conclusion

As Bioretec embarks on this rights issue, it continues to position itself at the forefront of medical device innovation while providing substantial opportunities for its shareholders. With the upcoming subscription period, existing investors may see this as a pivotal moment to deepen their engagement with a company that is committed to both advancing orthopedic treatment and fostering robust shareholder relationships.

For more information, potential investors and interested parties are encouraged to visit Bioretec's official website for the latest updates and details regarding the rights issue.